Update: Immuntherapien beim metastasierten NSCLC
PD Dr. med. Daniel Christoph
Gilead Sciences GmbH
ÜBER GILEAD
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Through bold and transformative science, we’re driving innovation that has the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.
https://www.gilead.com
https://www.gilead.com/utility/global-operations/europe/germany
ANSPRECHPARTNER GILEAD
 |
|
| Fr. Silvia Dambacher | Fr. Andra Kuske |
| Mail: silvia.dambacher@gilead.com | Mail: andra.kuske@gilead.com |